Johnson & Johnson
JNJHealthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson 10-Q filed Oct 22, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 24, 2025: 26 added · 20 removed · 52 modified; 15 with only figures updated; 6 moved without change
-
Modified · Analysis of consolidated sales
For the fiscal
sixnine months of 2025, worldwide sales were $45.669.6 billion, a total increase of4.15.0%, including an operational* increase of4.44.7% as compared to 2024 fiscalsixnine months sales of $43.866.3 billion. Currency fluctuations had anegativepositive impact of 0.3% for the fiscalsixnine months of 2025. In the fiscalsixnine months of 2025, acquisitions and divestitures had net positive impact of1.31.2%, on worldwide operational sales growth, primarily related to CAPLYTA and Shockwave. In the fiscalsixnine months of 2025, the negative impact of theStelaraSTELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately5.96.1%.